This company listing is no longer active
2VB Stock Overview
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Provention Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$21.60 |
| 52 Week High | US$22.78 |
| 52 Week Low | US$3.23 |
| Beta | 2.46 |
| 1 Month Change | -0.60% |
| 3 Month Change | 174.81% |
| 1 Year Change | 391.47% |
| 3 Year Change | 111.76% |
| 5 Year Change | n/a |
| Change since IPO | 495.04% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2VB | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -4.2% | -2.7% | -3.2% |
| 1Y | 391.5% | -21.9% | 7.6% |
Return vs Industry: 2VB exceeded the German Pharmaceuticals industry which returned -0.9% over the past year.
Return vs Market: 2VB exceeded the German Market which returned -3.3% over the past year.
Price Volatility
| 2VB volatility | |
|---|---|
| 2VB Average Weekly Movement | 65.7% |
| Pharmaceuticals Industry Average Movement | 4.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 2VB's share price has been volatile over the past 3 months.
Volatility Over Time: 2VB's weekly volatility has increased from 34% to 66% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2016 | 174 | Ashleigh Palmer | www.proventionbio.com |
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Provention Bio, Inc. Fundamentals Summary
| 2VB fundamental statistics | |
|---|---|
| Market cap | €2.15b |
| Earnings (TTM) | -€103.03m |
| Revenue (TTM) | €11.70m |
183.6x
P/S Ratio-20.8x
P/E RatioIs 2VB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2VB income statement (TTM) | |
|---|---|
| Revenue | US$12.90m |
| Cost of Revenue | US$76.32m |
| Gross Profit | -US$63.42m |
| Other Expenses | US$50.14m |
| Earnings | -US$113.56m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.20 |
| Gross Margin | -491.83% |
| Net Profit Margin | -880.69% |
| Debt/Equity Ratio | 19.3% |
How did 2VB perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/04/28 22:02 |
| End of Day Share Price | 2023/04/26 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Provention Bio, Inc. is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Alethia Young | Cantor Fitzgerald & Co. |
| Gbolahan Amusa Benz | Chardan Capital Markets, LLC |
| Taylor Feehley | Chardan Capital Markets, LLC |